Published in Cancer Epidemiol Biomarkers Prev on July 01, 2007
Bone marrow microenvironment and the identification of new targets for myeloma therapy. Leukemia (2008) 2.29
Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease. Blood (2011) 1.88
The link between the metabolic syndrome and cancer. Int J Biol Sci (2011) 1.37
Obesity and the risk for a hematological malignancy: leukemia, lymphoma, or myeloma. Oncologist (2010) 1.22
Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma. Cancer Epidemiol Biomarkers Prev (2009) 0.98
Body size and multiple myeloma mortality: a pooled analysis of 20 prospective studies. Br J Haematol (2014) 0.95
Body mass index and physical activity at different ages and risk of multiple myeloma in the NIH-AARP diet and health study. Am J Epidemiol (2013) 0.92
Anthropometric, behavioral, and female reproductive factors and risk of multiple myeloma: a pooled analysis. Cancer Causes Control (2013) 0.88
Bone marrow microenvironment in myelomagenesis: its potential role in early diagnosis. Expert Rev Mol Diagn (2010) 0.87
Multiple myeloma and physical activity: a scoping review. BMJ Open (2015) 0.85
The skinny on obesity and plasma cell myeloma: a review of the literature. Bone Marrow Transplant (2014) 0.84
Anthropometric characteristics and multiple myeloma risk. Epidemiology (2010) 0.80
Hostility and trajectories of body mass index over 19 years: the Whitehall II Study. Am J Epidemiol (2008) 0.79
Regular recreational physical activity and risk of hematologic malignancies: results from the prospective VITamins And lifestyle (VITAL) study. Ann Oncol (2012) 0.76
Nurses' Health Study Contributions on the Epidemiology of Less Common Cancers: Endometrial, Ovarian, Pancreatic, and Hematologic. Am J Public Health (2016) 0.75
Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser (1995) 57.68
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol (2003) 14.41
Validity of self-reported waist and hip circumferences in men and women. Epidemiology (1990) 10.57
Test of the National Death Index. Am J Epidemiol (1984) 8.46
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
Test of the National Death Index and Equifax Nationwide Death Search. Am J Epidemiol (1994) 6.47
Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab (1997) 5.84
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature (1988) 5.60
Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr (2006) 4.72
Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood (1989) 2.78
Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene (2002) 2.66
Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol (2005) 2.51
Relationship of total and abdominal adiposity with CRP and IL-6 in women. Ann Epidemiol (2003) 1.98
Anthropometric characteristics and risk of multiple myeloma. Epidemiology (2005) 1.85
Weight control and physical activity in cancer prevention. Obes Rev (2002) 1.79
Physical activity and mortality: a prospective study among women. Am J Public Health (2001) 1.78
Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest (1989) 1.72
Association of obesity and cancer risk in Canada. Am J Epidemiol (2004) 1.71
A population-based registry on paraproteinaemia in The Netherlands. Comprehensive Cancer Centre West, Leiden, The Netherlands. Br J Haematol (1997) 1.43
Smoking and risk of non-Hodgkin's lymphoma and multiple myeloma. Cancer Causes Control (1992) 1.35
Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood (1989) 1.35
Syndecan-1 and angiogenic cytokines in multiple myeloma: correlation with bone marrow angiogenesis and survival. Br J Haematol (2005) 1.18
Insulin-like growth factor I is a dual effector of multiple myeloma cell growth. Blood (2000) 1.17
Epidemiology and outcomes research for MGUS, myeloma and amyloidosis. Eur J Cancer (2006) 1.12
Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma. Cancer Epidemiol Biomarkers Prev (2006) 1.10
Multiple myeloma cells are protected against dexamethasone-induced apoptosis by insulin-like growth factors. Br J Haematol (1997) 1.09
Association between insulin-like growth factor-I: insulin-like growth factor-binding protein-1 ratio and metabolic and anthropometric factors in men and women. Cancer Epidemiol Biomarkers Prev (2004) 1.04
Smoking and the risk of leukemia, lymphoma, and multiple myeloma (Sweden). Cancer Causes Control (1998) 1.03
Receptor synergy of interleukin-6 (IL-6) and insulin-like growth factor-I in myeloma cells that highly express IL-6 receptor alpha [corrected]. Blood (2003) 1.02
Risk patterns of multiple myeloma in Los Angeles County, 1972-1999 (United States). Cancer Causes Control (2006) 1.02
Effects of weight control and physical activity in cancer prevention: role of endogenous hormone metabolism. Ann N Y Acad Sci (2002) 1.01
Myeloma and race: a review of the literature. Cancer Metastasis Rev (2003) 1.00
Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control (2001) 0.97
Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study. Haematologica (2004) 0.85
The spectrum of multiple myeloma: diagnostic and biological implications. Hum Pathol (1997) 0.77
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet (2007) 21.18
Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet (2008) 17.65
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med (2003) 16.11
Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med (2005) 15.30
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med (2008) 13.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
Sugar-sweetened beverages, weight gain, and incidence of type 2 diabetes in young and middle-aged women. JAMA (2004) 11.69
Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr (2006) 10.95
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer. Nat Genet (2009) 10.21
Television watching and other sedentary behaviors in relation to risk of obesity and type 2 diabetes mellitus in women. JAMA (2003) 10.05
Fruit and vegetable intake and risk of major chronic disease. J Natl Cancer Inst (2004) 8.77
Extended work shifts and the risk of motor vehicle crashes among interns. N Engl J Med (2005) 8.73
Benefits and harms of CT screening for lung cancer: a systematic review. JAMA (2012) 8.71
Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med (2004) 8.63
Physical activity and survival after breast cancer diagnosis. JAMA (2005) 8.60
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Long-term colorectal-cancer incidence and mortality after lower endoscopy. N Engl J Med (2013) 7.72
Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med (2012) 7.47
Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension (2007) 6.99
Diet quality and major chronic disease risk in men and women: moving toward improved dietary guidance. Am J Clin Nutr (2002) 6.96
Lenalidomide after stem-cell transplantation for multiple myeloma. N Engl J Med (2012) 6.24
Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA (2005) 5.95
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer (2007) 5.57
Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol (2006) 5.22
High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell (2006) 5.01
NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem (2002) 4.94
The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med (1990) 4.77
Merging and emerging cohorts: not worth the wait. Nature (2007) 4.66
Multiple myeloma. Lancet (2009) 4.60
Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood (2002) 4.56
Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood (2010) 4.52
Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci U S A (2003) 4.47
Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science (2011) 4.46
Increasing burden of melanoma in the United States. J Invest Dermatol (2009) 4.43
Sexual function in men older than 50 years of age: results from the health professionals follow-up study. Ann Intern Med (2003) 4.40
Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A (2002) 4.33
Moderate alcohol consumption during adult life, drinking patterns, and breast cancer risk. JAMA (2011) 4.25
Frequency of analgesic use and risk of hypertension in younger women. Arch Intern Med (2002) 4.21
Advances in biology of multiple myeloma: clinical applications. Blood (2004) 4.13
Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol (2005) 4.04
Comparison of risk factors for colon and rectal cancer. Int J Cancer (2004) 4.03
Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field. Gut (2010) 4.01
Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood (2011) 4.00
Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med (2010) 4.00
Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst (2006) 3.96
A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood (2006) 3.89
Estimating the number of deaths due to obesity: can the divergent findings be reconciled? J Womens Health (Larchmt) (2007) 3.86
Small-molecule inhibition of proteasome and aggresome function induces synergistic antitumor activity in multiple myeloma. Proc Natl Acad Sci U S A (2005) 3.86
Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol (2006) 3.79
The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell (2007) 3.76
Cancer risk prediction models: a workshop on development, evaluation, and application. J Natl Cancer Inst (2005) 3.75
The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood (2002) 3.73
Smoking and smoking cessation in relation to mortality in women. JAMA (2008) 3.68
Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood (2007) 3.66
Leisure time spent sitting in relation to total mortality in a prospective cohort of US adults. Am J Epidemiol (2010) 3.64
Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood (2002) 3.62
Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol (2006) 3.60
Zinc supplement use and risk of prostate cancer. J Natl Cancer Inst (2003) 3.54
The epidemic of obesity. J Clin Endocrinol Metab (2004) 3.53
A prospective study of aspirin use and the risk of pancreatic cancer in women. J Natl Cancer Inst (2004) 3.49
A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med (2004) 3.46
Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst (2004) 3.43
Proteasome inhibition as a novel therapeutic target in human cancer. J Clin Oncol (2005) 3.43
A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. Cancer Cell (2005) 3.41
Methods for pooling results of epidemiologic studies: the Pooling Project of Prospective Studies of Diet and Cancer. Am J Epidemiol (2006) 3.41
Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood (2006) 3.39
Obesity as compared with physical activity in predicting risk of coronary heart disease in women. Circulation (2006) 3.39
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Relation between dieting and weight change among preadolescents and adolescents. Pediatrics (2003) 3.36
Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA (2007) 3.34
Suicide rates among physicians: a quantitative and gender assessment (meta-analysis). Am J Psychiatry (2004) 3.31
Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A (2003) 3.30
Maternal gestational diabetes, birth weight, and adolescent obesity. Pediatrics (2003) 3.27
Extended work duration and the risk of self-reported percutaneous injuries in interns. JAMA (2006) 3.26
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell (2004) 3.25
Periodontal disease, tooth loss, and cancer risk in male health professionals: a prospective cohort study. Lancet Oncol (2008) 3.23
Impact of extended-duration shifts on medical errors, adverse events, and attentional failures. PLoS Med (2006) 3.22
Low plasma adiponectin levels and risk of colorectal cancer in men: a prospective study. J Natl Cancer Inst (2005) 3.22
Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol (2009) 3.21
Sexual orientation and tobacco use in a cohort study of US adolescent girls and boys. Arch Pediatr Adolesc Med (2004) 3.20
Standard chemotherapy compared with high-dose chemoradiotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol (2006) 3.20
Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med (2004) 3.18
American Cancer Society lung cancer screening guidelines. CA Cancer J Clin (2013) 3.16
Restoring systemic GDF11 levels reverses age-related dysfunction in mouse skeletal muscle. Science (2014) 3.14
A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (2006) 3.13
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood (2009) 3.12